Executive Summary
Midas Hygiene Industries challenged the Copyright Board's order that cancelled its copyright registrations for packaging material used on insecticide chalks. The core dispute revolved around whether the artistic work, when applied to a product, qualified as a 'design' under the Designs Act, thereby triggering the automatic cessation of copyright under Section 15(2) of the Copyright Act. Midas argued that the label was merely an artistic work and not a design in the statutory sense. The Delhi High Court set aside the Board's finding regarding Section 15(2), but remanded the matter for fresh consideration on issues of originality, locus standi, and limitation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Midas Hygiene Industries Pvt. Ltd. vs Sudhir Bhatia is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Mohd Anesur RahamanvsMosarraf Hossain And Ors
The Delhi High Court permitted the plaintiff, Mohd Anesur Rahaman, to amend his plaint in a trademark dispute. The amendment was necessary because the plaintiff had successfully registered the 'ANDAZ BIRI NO.205 LABEL' trademark during the pendency of the suit. This allows the plaintiff to formally pursue infringement claims based on the newly secured registration. The court emphasized that such amendments are allowed under principles of justice and equity to ensure all rights are properly adjudicated.
Star Scientific LimitedvsThe Controller Of Patents And Designs
Star Scientific Limited filed an appeal against the impugned order dated December 18, 2023, which rejected its patent application No. 20201711947 due to non-appearance on a scheduled hearing date. The appellant sought remand for hearing and condonation of delay in re-filing the appeal.
Duke UniversityvsDeputy Controller of Patents & Design
Duke University appealed the rejection of its patent application for 'LASOFOXIFENE TREATMENT OF ER+ BREAST CANCER' by the Deputy Controller. The Controller rejected the application, citing prior art and statutory objections (Sec. 2(1)(ja) and Sec. 3(i)), without permitting the appellant to amend its claims as requested.
E. R. Squibb And Sons, LlcvsZydus Lifesciences Limited
The plaintiffs are seeking a permanent injunction against the defendant for infringing their patent related to the pharmaceutical product NIVOLUMAB, marketed as OPDYTA in India. The defendant is attempting to process a biosimilar version of the plaintiff's drug.
Novartis AgvsTorrent Pharmaceuticals Limited
The Plaintiffs filed a suit for infringement of Indian Patent No. 229051, while the Defendant challenged the validity of the patent. The parties amicably resolved their disputes and sought a consent decree.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.